Cours W WORL

Actions

02/01/13	Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer
17/10/12	Pharmos Corp. Announces Management Changes
30/07/12	Pharmos Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012
17/05/12	Pharmos Corp. Announces Successfully Completion of Proof-Of-Concept Clinical Trial Using its Compound Levotofisopam to Treat Patients with Hyperuricemia and Gout
16/04/12	Pharmos Corp. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2012